new capsules which can be used to examine the oesophagus and colon. They may be used for patients who do not tolerate upper/ and/or lower gastrointestinal endoscopy. Also, reader software used for analysis has improved and newer capsules have increased battery lives with excellent lens resolution thus providing high definition images.
DETAILS OF TECHNOLOGY
Following an overnight fast, the patient swallows a small capsule measuring 26 mm x 11 mm and weighing 3.4 g (PillCam). It consists of a camera, light source, and a wireless circuit for the transmission of signals. As the capsule moves via peristalsis through the GI tract, images are transmitted to an external data recorder worn by the patient. The study usually lasts about 8 hours which is the lifespan of the battery. The data recorder is then connected to a computer and the images uploaded. These are then reviewed and analysed by a trained endoscopy reader. There are currently five types of VCE available in the UK: 
PATIENT GROUP AND USE
Use is indicated for:
• persistent unexplained iron deficiency anaemia (IDA);
• obscure GI bleeding with previously negative upper and lower endoscopies;
• assessment of small bowel lesions in known or suspected Crohn's disease;
• diagnosing and assessment of the small bowel in suspected coeliac disease;
• screening and surveillance in familial polyposis syndromes; and
• assessment and localisation of smallbowel tumours.
IMPORTANCE
Obscure GI bleeding accounts for approximately 5% of all overt GI bleeding cases 1 and the source is commonly from the small bowel. It is the most frequent indication for small bowel VCE 2 and can result in IDA. VCE should be performed after bidirectional endoscopy and after a repeat 'second-look' gastroscopy has failed to identify the source of bleeding. 3 Approximately 15% of the world's population suffer from IDA. 4 In the developed world, IDA occurs in 2-5% of adult men and postmenopausal women 5 and this accounts for 4-13% of referrals to gastroenterology. 6 The commonest cause is from menstrual losses in young women, however, blood loss from the GI tract is an important cause and current guidelines suggest that all men and postmenopausal women with IDA should undergo urgent endoscopic investigation. 5 VCE is indicated when bidirectional endoscopy is negative and IDA persists despite adequate iron replenishment. 5 Undetected and untreated, severe IDA can lead to fatigue, presyncope, and dyspnoea.
There are many possible causes of IDA or occult GI bleeding from the small bowel including: angiodysplasias, NSAID-associated ulceration, tumours, gastrointestinal stromal tumours, carcinoids, lymphoma, and Crohn's disease.
PREVIOUS RESEARCH
Accuracy compared to existing technology A meta-analysis has shown that complete imaging of the small bowel is achieved in 80% of VCE studies. 7 Limitations include poor bowel preparation, slow gut transit, and undiagnosed strictures. The completion rate is almost 100% in second-look studies and once strictures have been excluded.
In the investigation of obscure GI bleeding, another meta-analysis has shown that VCE has a significantly greater diagnostic yield (63%) compared with push enteroscopy (23%). 8 A study has also shown that VCE detected a bleeding source in 72% of patients, compared to 24% by CT angiography and 56% by standard angiography. 9 Intraoperative enteroscopy is currently the gold standard for investigating obscure GI bleeding from the small bowel. In comparison, VCE has been shown to have a sensitivity, specificity, positive and negative predictive values of 95%, 75%, 95% and 86%, respectively. 10 Impact compared to existing technology VCE is now considered to be the first line test for investigating the small bowel. It is easy to perform, minimally invasive, and unlike previous radiological investigations, does not involve ionising radiation. Prior to the advent of VCE, investigation of the small bowel was incredibly challenging. Compared to other small bowel investigations, VCE remains the safest investigation of the small bowel.
The limitations and risks associated with VCE are small. The risk of VCE retention is under 1.5% but is higher in patients with Crohn's disease (5-13%). 11 Most retained capsules eventually pass spontaneously with no sequelae, but balloon enteroscopy or surgery may be necessary for VCEs persistently retained after 2 weeks.
The contraindications of VCE are:
• presence of known intestinal strictures, fistulas, or obstruction;
• small and/or young children;
• patients with swallowing disorders (but VCEs can be easily placed with a gastroscope and biopsy forceps if necessary);
• pregnancy (relatively contraindicated); and
• concurrent MRI examination.
The limitations of VCE are: • missed lesions due to reader error or technical malfunction;
• unable to obtain biopsies or perform therapeutic interventions;
• the position of the capsule cannot be accurately controlled;
• potentially obstructed views from inadequate bowel preparation; and
• subjectivity of interpretation of images by the observer.
The ease of performing VCE in an ambulatory outpatient setting makes it an attractive investigation to be performed in primary care. Nurse endoscopists and GPs with a special interest in endoscopy may wish to provide a VCE service in primary care.
Cost-effectiveness and economic impact
The current cost of a single use capsule is in the region of £300.
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A cost-effectiveness analysis study was performed to explore the optimal strategy for investigating obscure GI bleeding. Five small bowel investigations were compared to a no therapy reference and the authors found that an initial doubleballoon enteroscopy was the most costeffective approach. However, due to the significant resources required and potential complications involved, it was concluded that VCE should be performed to guide subsequent treatment before invasive endoscopy. 13 Another retrospective cost-effectiveness study found VCE to be a cost-saving approach in the evaluation of patients with obscure GI bleeding. The VCE diagnostic yield was compared to other imaging modalities and evaluated as a measure of efficacy. The mean cost of a positive diagnosis with VCE was €2091 compared with €3829 for other procedures. Therefore, one positive diagnosis by VCE provided a mean cost saving of €1738.
14 Provenance Freely submitted; externally peer reviewed.
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